Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
05 nov. 2024 09h30 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for...
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
05 nov. 2024 09h05 HE
|
Agios Pharmaceuticals, Inc.
Agios announced new data on mitapivat and tebapivat (AG-946) will be featured in oral and poster presentations during the ASH Annual Meeting.
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting
12 janv. 2024 08h45 HE
|
International Myeloma Foundation
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at ASH 2023
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
09 déc. 2023 20h30 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
09 déc. 2023 19h00 HE
|
Agios Pharmaceuticals, Inc.
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
09 déc. 2023 18h30 HE
|
Aptose Biosciences, Inc.
ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
02 nov. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting
02 nov. 2023 15h18 HE
|
NovalGen Ltd.
NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting
Fly Ash Market to Reach $45.73Bn by 2028 at 4.8% CAGR with Type C Fly Ash Segment Driving Growth During 2021–2028 | The Insight Partners
05 juil. 2023 07h55 HE
|
The Insight Partners
Pune, India, July 05, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Fly Ash Market Size Report, Share, Growth Strategy, Industry Trends, and Forecast to 2028-...
Florida Cancer Specialists & Research Institute Research Breakthroughs Presented at Global Hematology Gathering
13 déc. 2022 09h17 HE
|
Florida Cancer Specialists & Research Institute
Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) that is contributing to global advancements in the...